Filing Analysis
Palisade Bio, Inc. issued an 8-K to announce its financial results for the three and six months ended June 30, 2026. The filing serves as a formal notice that a press release containing these results was issued on August 10, 2026.
📋 Key Facts
- Reporting period: Three and six months ended June 30, 2026.
- Announcement date: August 10, 2026.
- The filing includes a press release as Exhibit 99.1 regarding financial results.
Palisade Bio held its 2026 Annual Meeting of Stockholders on June 10, 2026, resulting in a significant increase in authorized common stock and the appointment of a new director. The company also approved amended equity incentive and employee stock purchase plans.
🚩 Red Flags
- Significant increase in authorized shares (50% increase from 300M to 450M), which typically signals potential future dilution for existing shareholders.
- Multiple 8-K items (5.02, 5.03, 5.07) reported in a single filing.
- High equity grant ($566,000) for a new non-employee director relative to typical micro-cap compensation.
📋 Key Facts
- Authorized common stock increased from 300,000,000 to 450,000,000 shares, effective June 11, 2026.
- Jordan Zwick was appointed to the Board of Directors and the Audit Committee, receiving an initial RSU grant valued at $566,000 vesting over three years.
- Stockholders approved the Amended and Restated 2021 Equity Incentive Plan and the Amended and Restated 2021 Employee Stock Purchase Plan.
- Baker Tilly US, LLP was ratified as the independent registered public accounting firm for fiscal year ending December 31, 2026.
- Four directors were elected: J.D. Finley, Donald Williams, Emil Chuang, and Robert F. Baltera, Jr.
Palisade Bio, Inc. announced its financial results for the first fiscal quarter ended March 31, 2026. The announcement was made via a press release and filed under Item 2.02 of Form 8-K.
📋 Key Facts
- The report covers the three months ended March 31, 2026.
- The filing was made on May 12, 2026, the same day as the press release.
- The information is furnished under Item 2.02 and is not deemed 'filed' for purposes of Section 18 of the Exchange Act.
- J.D. Finley, Chief Executive Officer, signed the report.
Palisade Bio entered into a strategic partnership with Iterative Health to expedite Phase 2 clinical trial enrollment for PALI-2108 and simultaneously secured a $3.0 million private placement investment from an affiliate of the partner.
🚩 Red Flags
- The transaction involves a private placement (PIPE), which results in immediate dilution of existing shareholders.
📋 Key Facts
- Entered into a Master Services Agreement (MSA) with Iterative Scopes, Inc. (d/b/a Iterative Health) on March 30, 2026.
- The MSA is designed to assist with Study Enrollment for a Phase 2 study of PALI-2108 for moderate to severe Ulcerative Colitis.
- Issued and sold 1,536,885 shares of common stock to an affiliate of Iterative Health on March 27, 2026.
- The total purchase price was $3.0 million, representing $1.952 per share.
- The share price was calculated based on the average closing price for the five trading days prior to the Closing Date.
Palisade Bio, Inc. held a special meeting of stockholders on December 3, 2025, where shareholders approved two key proposals: the issuance of shares underlying warrants and an increase in authorized common stock. The approval of warrant exercises is significant as it involves shares exceeding 20% of the company's outstanding common stock.
🚩 Red Flags
- Warrant inducement agreement involves issuance of shares exceeding 20% of common stock, which typically leads to significant dilution for existing shareholders.
- Increase in authorized shares (from 280M to 300M) provides the company with more 'dry powder' for future equity financing/dilution.
📋 Key Facts
- Stockholders approved a proposal to issue up to 8,637,810 shares underlying certain warrants (pursuant to Nasdaq Listing Rule 5635(d)).
- The warrant issuance represents an amount equal to or in excess of 20% of the Company's common stock outstanding prior to issuance.
- Stockholders approved an amendment to increase authorized common stock from 280,000,000 to 300,000,000 shares.
- The total number of authorized capital stock will increase from 287,000,000 to 307,000,000 shares.
- Quorum was met with 127,404,008 shares present (approx. 85.53% of outstanding shares as of the record date).
- The warrant exercise proposal passed with 104,727,000 votes in favor.
Palisade Bio, Inc. has terminated its Phantom Unit Plan effective October 22, 2025. This action results in the immediate termination of unvested phantom units for the CEO, CMO, and SVP of Finance without consideration.
🚩 Red Flags
- Rapid succession: The plan was approved on Sept 4 and terminated by Oct 22 (less than 2 months later).
- Forfeiture of compensation: Key executives (CEO, CMO, SVP Finance) are losing unvested equity/incentives without consideration.
- Potential indicator of restructuring or significant internal shifts given the speed of plan termination.
📋 Key Facts
- The Board approved a Phantom Unit Plan on September 4, 2025.
- On October 22, 2025, the Company approved the termination of said Plan.
- Unvested Phantom Units held by J.D. Finley (CEO), Mitchell Jones (CMO), and Ryker Willie (SVP of Finance) will terminate for no consideration.
- The plan was originally intended to provide compensatory awards to employees, directors, and consultants.
Palisade Bio, Inc. held its annual meeting of stockholders on October 17, 2025, where shareholders approved an amendment to allow the Board of Directors to execute a reverse stock split between ratios of 1-for-5 and 1-for-50 by year-end.
🚩 Red Flags
- Approval of a wide range for a reverse stock split (up to 1-for-50) often indicates efforts to maintain Nasdaq compliance regarding minimum bid price requirements.
- High number of 'Votes Against' the reverse split proposal (1,122,616 votes), indicating significant shareholder opposition.
📋 Key Facts
- Annual Meeting held on October 17, 2025.
- Quorum was established with 3,585,700 shares (approx. 39.32% of outstanding shares) present.
- Three directors elected: J.D. Finley, Donald Williams, and Emil Chuang.
- Baker Tilly US, LLP ratified as the independent registered public accounting firm for FY2025.
- Stockholders approved a reverse split ratio between 1-for-5 and 1-for-50 to be implemented by December 31, 2025.
Palisade Bio, Inc. announced that it has successfully regained compliance with Nasdaq's minimum bid price requirement ($1.00), resolving a delisting notice received in April 2025. The company also provided an update on its cash position and outstanding share count.
🚩 Red Flags
- Significant dilution potential from 73.2 million pre-funded warrants.
- Historical volatility/risk: The company was under a delisting threat until very recently (compliance deadline was Oct 27, 2025).
📋 Key Facts
- As of October 15, 2025, the Company reported approximately $133.3 million in cash and cash equivalents.
- There are 133,002,572 shares of common stock outstanding.
- Pre-funded warrants exist to purchase up to 73,271,424 shares of common stock.
- The Company regained compliance with Nasdaq Listing Rule 5550(a)(2) (Minimum Bid Price Requirement) as of October 15, 2025.
Palisade Bio, Inc. has announced the cancellation of its special meeting of stockholders scheduled for October 10, 2025. The company is withdrawing all proposals previously set forth in its August 18, 2025 proxy statement from stockholder consideration.
🚩 Red Flags
- Abrupt cancellation of a special meeting scheduled for the following day suggests significant internal volatility or failed negotiations regarding shareholder proposals.
📋 Key Facts
- Special Meeting originally scheduled for October 10, 2025, at 10:00 a.m. PT has been cancelled.
- The company is withdrawing all proposals contained in the definitive proxy statement filed on August 18, 2025.
- Announcement made via press release dated October 9, 2025.
Palisade Bio, Inc. adjourned its special meeting of stockholders on September 26, 2025, due to a lack of quorum. The meeting is rescheduled for October 10, 2025.
🚩 Red Flags
- Failure to reach a quorum suggests low shareholder engagement or potential opposition/apathy regarding the proposals being voted upon.
- Delay in corporate actions (Special Meeting) can impact timelines for critical company decisions such as restructuring, capital raises, or governance changes.
📋 Key Facts
- Special Meeting convened on September 26, 2025, but failed to reach a quorum.
- Meeting adjourned without conducting business.
- Rescheduled Special Meeting date: Friday, October 10, 2025, at 10:00 a.m. PT.
- Record date remains July 28, 2025.
- Proposals to be voted on remain unchanged from the August 18, 2025 proxy statement.
Palisade Bio, Inc. adjourned its special meeting of stockholders on September 18, 2025, due to a lack of quorum. The meeting is scheduled to reconvene on September 26, 2025.
🚩 Red Flags
- Failure to reach a quorum suggests low shareholder engagement or potential opposition/apathy regarding the matters being voted on.
- The inability to conduct business at a special meeting can delay critical corporate actions (e.g., restructuring, officer elections, or capital raises).
📋 Key Facts
- Special Meeting convened on September 18, 2025, but failed to reach a quorum.
- The adjourned Special Meeting is set for Friday, September 26, 2025, at 10:00 a.m. PT.
- The record date remains July 28, 2025.
- No changes have been made to the original proposals being voted upon.
Palisade Bio, Inc. has adopted a new Phantom Unit Plan and simultaneously amended the employment agreements for its CEO/CFO, CMO, and SVP of Finance. The filing also details significant phantom unit grants to these executives and various directors.
🚩 Red Flags
- Significant expansion of executive compensation via cash-settled phantom units which may create future liquidity obligations.
- Enhanced severance packages (double trigger) for executives during 'Change in Control' periods, specifically up to 24 months of salary and 2x bonus.
📋 Key Facts
- Board approved a new Phantom Unit Plan on September 4, 2025, allowing for up to 10,000,000 cash-settled units.
- CEO J.D. Finley granted 323,400 phantom units; CMO Mitchell Jones granted 289,000; SVP of Finance Ryker Willie granted 137,600.
- Amended employment agreement for CEO/CFO includes a base salary of $575,000 and potential severance of 24 months' salary plus 2x bonus in the event of a Change in Control.
- Executive phantom units vest over three years in quarterly installments; director units vest over three years in annual installments.
- Trigger events for phantom unit payments include Liquidity/Change in Control, termination without cause, or reaching the 7th anniversary of grant.
Palisade Bio, Inc. entered into a warrant inducement agreement to facilitate the exercise of existing warrants by an institutional holder at a reduced price of $0.9047 per share. The deal includes the issuance of new warrants representing 200% coverage and requires shareholder approval due to Nasdaq compliance requirements.
🚩 Red Flags
- Significant potential dilution: The issuance of new warrants covering up to 8.6M shares represents a massive increase in the float.
- Warrant Inducement: Using price reductions and 'sweeteners' (200% coverage) is often a sign of liquidity distress or difficulty raising capital through standard means.
- Nasdaq Compliance Risk: The need for shareholder approval for warrant issuance indicates potential non-compliance with Nasdaq rules regarding dilution/ownership limits.
📋 Key Facts
- The company expects gross proceeds of approximately $3.9 million from the exercise of 4,318,905 existing warrants.
- Exercise price for existing warrants reduced to $0.9047 per share.
- Issuance of 'New Warrants' covering up to 8,637,810 shares (200% coverage) at an exercise price of $0.9047.
- The transaction requires stockholder approval; a meeting must be held within 60 days of July 23, 2025.
- Ladenburg Thalmann & Co., Inc. acting as placement agent with an 8% cash fee and 1% management fee.
- Company is prohibited from entering into more favorable warrant inducement agreements for 30 days.
Palisade Bio, Inc. announced the resignation of Board member Margery Fischbein and the appointment of Dr. Emil Chuang to the Board and its various committees.
🚩 Red Flags
- Acceleration of equity vesting (3,100 options) for a departing director is often viewed with caution, though here it is framed as recognition of service.
📋 Key Facts
- Margery Fischbein resigned from the Board effective July 2, 2025; her departure is not due to any disagreement with the Company.
- The Board accelerated the vesting of 3,100 outstanding stock options for Ms. Fischbein upon her resignation.
- Dr. Emil Chuang was elected to the Board on July 7, 2025, to fill a vacancy.
- Dr. Chuang will serve on the Audit Committee, Compensation Committee, and Governance and Nominating Committee.
- Dr. Chuang will receive a non-statutory stock option for 8,000 shares of common stock.
Palisade Bio, Inc. received a notice from Nasdaq stating the company is in violation of the minimum bid price requirement after its stock closed below $1.00 for 30 consecutive trading days.
🚩 Red Flags
- Delisting notice from Nasdaq
- Prolonged period (30 consecutive trading days) of sub-$1.00 share price indicates significant market loss of confidence or liquidity issues.
📋 Key Facts
- Notice received on April 30, 2025.
- Violation of Nasdaq Listing Rule 5550(a)(2) regarding the $1.00 minimum bid price requirement.
- The company has a 180-day compliance period to regain compliance by maintaining a closing bid price of at least $1.00 for 10 consecutive business days.
- A potential additional 180-day 'Additional Compliance Period' may be available if market value requirements are met.
- The company's stock continues to trade on the Nasdaq Capital Market under symbol 'PALI'.
Palisade Bio, Inc. completed a public offering of Class A and Class B units on December 13, 2024, raising approximately $4.10 million in net proceeds. The offering included significant issuance of warrants and the repricing of existing warrants to lower exercise prices.
🚩 Red Flags
- Significant dilution via the issuance of over 3 million Class B Units containing prefunded warrants and common warrants.
- Warrant repricing (lowering exercise price to $1.40) for existing investors, which is a dilutive event for current shareholders.
- Heavy reliance on equity financing to fund clinical trials and working capital.
📋 Key Facts
- Public offering closed on December 13, 2024.
- Issued 158,000 Class A Units at $1.525 per unit (includes one common stock and one common warrant).
- Issued 3,120,688 Class B Units at $1.5249 per unit (includes one prefunded warrant and one common warrant).
- Net proceeds to the company are approximately $4.10 million.
- Proceeds intended for Phase 1 clinical trial of PALI-2108, pre-clinical studies, R&D, and working capital.
- Repriced 1,040,217 existing warrants from various expiration dates to a new exercise price of $1.40 per share.
- Total common stock outstanding as of Dec 13, 2024: 2,765,980 shares.
Palisade Bio, Inc. entered into a revised employment agreement with its current CEO and CFO, J.D. Finley, effective September 25, 2024. The agreement maintains his existing base salary but outlines specific severance terms in the event of termination or a change in control.
🚩 Red Flags
- Dual role as CEO and CFO can sometimes indicate resource constraints or lack of depth in management structure in micro-cap firms.
📋 Key Facts
- Effective Date: September 25, 2024.
- Role: J.D. Finley serves as both Chief Executive Officer and Chief Financial Officer.
- Base Salary: $542,000 per year (no increase from previous levels).
- Bonus Structure: Eligible for an annual cash bonus with a target of up to 50% of base salary based on performance goals.
- Standard Severance: If terminated without 'Cause' or resignation for 'Good Reason', eligible for 12 months of base salary and COBRA benefits.
- Change in Control Severance: If termination occurs within a specified window around a Change in Control, severance increases to 18 months of base salary plus 100% of target bonus and accelerated equity vesting.
Palisade Bio, Inc. held its annual meeting of stockholders on July 8, 2024. The company successfully elected three directors and ratified the selection of Baker Tilly US, LLP as its independent auditor for the fiscal year ending December 31, 2024.
📋 Key Facts
- Annual Meeting held on July 8, 2024.
- Quorum was established with 380,286 shares present (approx. 40.61% of outstanding shares).
- Three directors elected: J.D. Finley, Donald Williams, and Margery Fischbein.
- Baker Tilly US, LLP ratified as independent registered public accounting firm for FY2024.
Palisade Bio, Inc. announced the appointment of Margery Fischbein to its Board of Directors and Audit Committee, effective May 7, 2024.
📋 Key Facts
- Margery Fischbein appointed to the Board of Directors effective May 7, 2024.
- Ms. Fischbein will serve on the Company's audit committee as she has been determined to be independent.
- The Board now consists of four (4) acting directors.
- Compensation includes an option to purchase 1,000 shares of common stock with an exercise price of $7.90 per share, vesting over three years in quarterly installments.
Palisade Bio, Inc. entered into a securities purchase agreement on May 1, 2024, to conduct a private placement of common stock and prefunded warrants for approximately $4.0 million in gross proceeds. The offering includes significant warrant coverage and requires the company to file an S-3 registration statement within 10 days of closing.
🚩 Red Flags
- Significant dilution potential due to high volume of prefunded warrants and additional warrants.
- Prefunded warrants with near-zero exercise price ($0.0001) act as immediate equity issuance upon conversion.
- High placement agent fee (7.75%) plus expenses and warrants.
- Requirement to file S-3 within 10 days suggests an urgent need for liquidity or a requirement from the investor.
📋 Key Facts
- Offering date: May 1, 2024; Expected close: on or about May 6, 2024.
- Total gross proceeds: approximately $4.0 million (before fees).
- Securities issued: 85,100 shares of common stock and 530,142 prefunded warrants at $6.5015 per unit.
- Prefunded Warrants: Exercisable immediately with an exercise price of $0.0001 per share.
- Additional Warrants: 922,863 common stock warrants issued to the purchaser with an exercise price of $6.314 and a 7-year term.
- Registration Rights Agreement: Company must file Form S-3 within 10 days of closing and declare it effective within 60 days.
- Placement Agent: Ladenburg Thalmann & Co. Inc. receiving 7.75% cash fee plus up to $75,000 in expenses.
Palisade Bio, Inc. announced its presentation at the IBD Innovate: Product Development for Crohn’s & Colitis™ conference held in Cambridge, MA. The presentation focused on the development and strategic positioning of their PALI-2108 candidate.
📋 Key Facts
- Presented at 'IBD Innovate: Product Development for Crohn’s & Colitis™' from April 9-10, 2024.
- Presentation title: 'Advancing PALI-2108: Discover to Strategy Positioning'.
- The filing includes a press release (Exhibit 99.01) and presentation slides (Exhibit 99.02).
Palisade Bio, Inc. has implemented a 1-for-15 reverse stock split effective April 5, 2024, following shareholder approval on March 25, 2024. The action reduces the total outstanding common shares from approximately 12.77 million to roughly 851,401 shares.
🚩 Red Flags
- Reverse stock split (often used to maintain Nasdaq listing requirements or mitigate extreme dilution/low share price).
- Significant reduction in share count (93.3% reduction) which can indicate a distressed capital structure.
📋 Key Facts
- Reverse stock split ratio: 1-for-15.
- Effective date of Amendment: April 5, 2024, at 5:00 p.m. ET.
- Post-split common shares outstanding: Approximately 851,401 (down from 12,771,015).
- New CUSIP number for Common Stock: 696389402.
- Trading on Nasdaq Capital Market resumes April 8, 2024, under symbol 'PALI'.
- Fractional shares will be paid in cash based on the closing price on April 5, 2024.
Palisade Bio, Inc. announced the approval of a shareholder proposal to implement a reverse stock split with a ratio between 1-for-2 and 1-for-15. Additionally, the company received a Nasdaq notice regarding non-compliance with audit committee requirements.
🚩 Red Flags
- Reverse stock split approved (often used to maintain minimum bid price for Nasdaq listing).
- Nasdaq non-compliance notice regarding audit committee composition.
- Potential delisting risk if compliance is not achieved within the cure period.
📋 Key Facts
- Shareholders approved an amendment to effect a reverse stock split at a ratio between 1-for-2 and 1-for-15 by December 31, 2024.
- Nasdaq issued a notice on March 22, 2024, stating the company is not in compliance with Nasdaq Listing Rule 5605 (audit committee requirements).
- The audit committee currently has only two members; Nasdaq requires three independent directors.
- A cure period was granted to regain compliance by either the next annual meeting or March 4, 2025 (or September 3, 2024, if the meeting is held earlier).
- The company reported its full-year 2023 financial results on March 26, 2024.
Palisade Bio, Inc. announced the immediate resignation of Board member Mary Ann Gray, Ph.D., and a significant amendment to its bylaws regarding board structure.
🚩 Red Flags
- Sudden departure of a board member (though no disagreement was noted).
📋 Key Facts
- Mary Ann Gray, Ph.D. resigned from the Board effective March 4, 2024.
- The company stated Dr. Gray's resignation was not due to any disagreement with operations, policies, or practices.
- On February 29, 2024, the Board adopted Amended and Restated Bylaws.
- The bylaws amendment removes the classified (staggered) Board structure in favor of annual elections for all directors.
Palisade Bio, Inc. announced the immediate resignation of four board members: James Neal, Stephanie Diaz, Dr. Cristina Csimma, and Dr. Robert Trenschel.
🚩 Red Flags
- Mass resignation of four board members simultaneously is highly unusual for a micro-cap company and often signals internal instability or strategic shifts.
- The 'immediate' nature of the departures can be a sign of sudden governance changes.
📋 Key Facts
- Four directors resigned effective between February 8, 2024, and February 9, 2024.
- The resigning directors are James Neal, Stephanie Diaz, Dr. Cristina Csimma, and Dr. Robert Trenschel.
- The company stated that the resignations were not due to any disagreement with the Company regarding operations, policies, or practices.
Palisade Bio, Inc. entered into warrant inducement agreements to encourage the exercise of existing warrants by reducing their exercise price to $0.7313 per share. The transaction will result in the issuance of 3,422,286 shares of common stock and provides approximately $2.5 million in gross proceeds.
🚩 Red Flags
- Warrant Inducement: Significant dilution through exercise price reduction.
- Liquidation Damages: Company is liable for liquidated damages if it fails to register replacement warrants or remove restrictive legends timely.
- Cashless Exercise Provision: Replacement warrants may be exercised on a cashless basis after 6 months if not registered, potentially increasing immediate dilution pressure.
📋 Key Facts
- Date of Agreement: January 30, 2024
- Exercise price reduction to $0.7313 per share for existing warrants.
- Total shares to be issued upon exercise: 3,422,286 common stock shares.
- Anticipated gross proceeds: approximately $2,502,717 (excluding fees).
- Holders receive one replacement warrant for each existing warrant exercised; replacement warrants expire in 5 years.
- Placement Agent (Ladenburg Thalmann & Co., Inc.) to receive a 7.75% cash fee and a warrant for 6% of the shares issued.
Palisade Bio, Inc. announced the presentation of positive preclinical data for its lead asset, PALI-2108, at the Crohn’s & Colitis Congress. The company also released an informative video featuring its CEO and CMO discussing current developments.
🚩 Red Flags
- None identified in this specific filing.
📋 Key Facts
- Presented positive preclinical data for lead asset PALI-2108 (a PDE4 inhibitor prodrug) at the Crohn's & Colitis Congress (Jan 25-27, 2024).
- The presentation focused on 'Local Bioactivation and Efficacy of PALI-2108 for Ulcerative Colitis Treatment'.
- Released an informative video featuring the CEO and Chief Medical Officer regarding company developments.